Spectrum Pharmaceuticals Provides Update on Belinostat Registrational Trial ... MarketWatch (press release) The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targeted biologic monoclonal antibody augmented with the therapeutic effects of a ... |
